ImClone appoints former J&J exec as CEO

Share this article:

ImClone Systems said Thursday that former Johnson & Johnson executive John Johnson will take over as CEO effective Aug. 27.

Johnson most recently served as group chairman of J&J's worldwide biopharmaceuticals unit and has held various senior management positions at J&J.

ImClone had previously been run by a committee created when investor Carl Icahn took over the company and ousted its top officials 10 months ago. 
 
Johnson has a challenging job ahead as ImClone looks to expand its pipeline and the market for its only product Erbitux, currently approved for use to treat cancers of the head and neck and colorectal cancers.

ImClone and marketing partner Bristol Myers-Squibb had hoped to win approval for Erbitux as a lung cancer treatment however a recent late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...